Selective Neoadjuvant Treatment According to Immunohistochemical Subtype for HER2 Negative Breast Cancer Patients
Status:
Completed
Trial end date:
2010-09-01
Target enrollment:
Participant gender:
Summary
This is an open-label study that includes two substudies of random distribution. First,a
sample of the primary tumor will be obtained and will be analyzed by an immunohistochemical
technique to determine several markers.Depending on the expression of these markers, the
patients will be characterize as group 1 (Luminal A phenotype) or group 2 (Basal phenotype)
and a random assignment will be performed to standard or experimental treatment.